Efficacy and safety of eflornithine (CPP-1X)/sulindac combination therapy versus each as monotherapy in patients with familial adenomatous polyposis (FAP): Design and rationale of a randomized, double-blind, Phase III trial

Carol A. Burke, Evelien Dekker, N. Jewel Samadder, Elena Stoffel, Alfred Cohen

Research output: Contribution to journal › Article › peer-review

18 Scopus citations

Fingerprint

Dive into the research topics of 'Efficacy and safety of eflornithine (CPP-1X)/sulindac combination therapy versus each as monotherapy in patients with familial adenomatous polyposis (FAP): Design and rationale of a randomized, double-blind, Phase III trial'. Together they form a unique fingerprint.

Medicine & Life Sciences